1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Larimar Therapeutics said it has submitted the first module of a rolling Biologics License Application to the FDA for accelerated approval of nomlabofusp, after FDA meeting minutes said the existing data package appears sufficient for submission. The company also reported longer-term open label data, which showed improvements in some clinical measures alongside anaphylaxis in 10 of 43 patients, a safety finding shareholders should weigh.
First module of the rolling BLA submitted; remaining modules expected in the second half of 2026.
FDA meeting minutes say the existing data package appears sufficient for a BLA seeking accelerated approval; approval will be a matter of review.
Anaphylaxis occurred in 10 of 43 patients in the open label study, 9 of whom had prior exposure to nomlabofusp.
At 1 year, 100% (9/9) of participants had skin FXN levels above 50% of healthy volunteer mean; first patient dosing in a global Phase 3 study is expected in Q3 2026.
Atlas Lithium said the Minas Gerais permitting commission voted on June 26, 2026 to grant its expansion permit, applied for on November 25, 2024, and the decision was published in the state gazette on June 27, 2026. The permit covers additional mining areas and authorizes assembling and operating its lithium processing plant, processing mined ore there, and selling the lithium concentrate it produces, which the company says positions it to advance its Neves Project.
Permitting commission vote granting the expansion permit: June 26, 2026
Official gazette publication in Minas Gerais, Brazil: June 27, 2026
Permit covers additional mining areas beyond those in the operational permit received October 25, 2024
Permit authorizes plant assembly and operation, ore processing, and sale of lithium concentrate
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.